Literature DB >> 11802203

High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma.

Johanna Nikkola1, Pia Vihinen, Tatyana Vlaykova, Marjo Hahka-Kemppinen, Veli-Matti Kähäri, Seppo Pyrhönen.   

Abstract

Matrix metalloproteinases (MMPs) are proteolytic enzymes capable of degrading extracellular matrix. Their role has been emphasized in tumor invasion, metastasis and tumor-induced angiogenesis. We studied the expression of collagenase-1 (MMP-1), stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) in 70 melanoma metastases obtained from 56 patients treated with combined chemoimmunotherapy. The patients were divided into 2 groups using a cut-off point of 0% for MMP-1 expression and 20% for MMP-3 expression. We found that patients with MMP-1 positive metastases (n = 38) had significantly shorter disease-free survival compared to patients with MMP-1 negative metastases (n = 18) (median 11.2 vs. 17.0 months, p = 0.0383). The disease-free survival of patients with high levels of MMP-3 expression in their metastases (> or = 20% positive tumor cells, n = 14) was also significantly shorter compared to patients with lower levels of expression (n = 42) (median 5.1 vs. 14.0 months, p = 0.0294). The expression of MMP-13 did not correlate to survival parameters. We also found that the presence of melanin, a pigment produced by melanocytes, correlated with high expression levels of MMP-1 (p = 0.0002), MMP-3 (p < 0.0001) and MMP-13 (p = 0.0009). The high expression levels of MMP-13 were also associated with the presence of visceral metastases (p = 0.0284). Our findings suggest that MMP-1 and -3 may have a special role in melanoma metastasis formation and thus they could be used to measure the biological activity of the disease. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11802203     DOI: 10.1002/ijc.1636

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  42 in total

1.  Variability in melanoma metalloproteinase expression profiling.

Authors:  Orsi Giricz; Janelle L Lauer; Gregg B Fields
Journal:  J Biomol Tech       Date:  2010-12

2.  Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition.

Authors:  Jennifer L Leight; Emi Y Tokuda; Caitlin E Jones; Austin J Lin; Kristi S Anseth
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

3.  Evaluation of two (125)I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma.

Authors:  Maryline Gardette; Claire Viallard; Salomé Paillas; Jean-Luc Guerquin-Kern; Janine Papon; Nicole Moins; Pierre Labarre; Nicolas Desbois; Pascal Wong-Wah-Chung; Sabine Palle; Ting-Di Wu; Jean-Pierre Pouget; Elisabeth Miot-Noirault; Jean-Michel Chezal; Francoise Degoul
Journal:  Invest New Drugs       Date:  2014-04-02       Impact factor: 3.850

4.  Distinct biological events generated by ECM proteolysis by two homologous collagenases.

Authors:  Inna Solomonov; Eldar Zehorai; Dalit Talmi-Frank; Sharon G Wolf; Alla Shainskaya; Alina Zhuravlev; Elena Kartvelishvily; Robert Visse; Yishai Levin; Nir Kampf; Diego Adhemar Jaitin; Eyal David; Ido Amit; Hideaki Nagase; Irit Sagi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-14       Impact factor: 11.205

Review 5.  Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.

Authors:  Eleonore Fröhlich
Journal:  Cell Mol Life Sci       Date:  2010-08-05       Impact factor: 9.261

6.  MMP-21 is upregulated at early stages of melanoma progression but disappears with more aggressive phenotype.

Authors:  Tiina Kuivanen; Katja Ahokas; Susanna Virolainen; Tiina Jahkola; Erkki Hölttä; Olli Saksela; Ulpu Saarialho-Kere
Journal:  Virchows Arch       Date:  2005-08-20       Impact factor: 4.064

7.  Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma.

Authors:  Faruk Tas; Derya Duranyildiz; Hilal Oguz; Rian Disci; Sidika Kurul; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

8.  Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis.

Authors:  C J Foley; M Fanjul-Fernández; A Bohm; N Nguyen; A Agarwal; K Austin; G Koukos; L Covic; C López-Otín; A Kuliopulos
Journal:  Oncogene       Date:  2013-05-27       Impact factor: 9.867

9.  The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression.

Authors:  Eric Guenzi; Kristin Töpolt; Clara Lubeseder-Martellato; Anita Jörg; Elisabeth Naschberger; Roberto Benelli; Adriana Albini; Michael Stürzl
Journal:  EMBO J       Date:  2003-08-01       Impact factor: 11.598

10.  14-3-3 proteins modulate the ETS transcription factor ETV1 in prostate cancer.

Authors:  Sangphil Oh; Sook Shin; Stan A Lightfoot; Ralf Janknecht
Journal:  Cancer Res       Date:  2013-06-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.